Stockholm – 22 February 2011 ‐ Karolinska Development AB today announced that Benjamin Nordin has been appointed Investor Relations Director. In this new role, Benjamin will be responsible for both Business Analysis and Communication.
"Benjamin fits very well in this new role. As Head of Business Analysis, Benjamin has a deep and broad understanding of Karolinska Development and its portfolio companies. He also has a background as an equity analyst, which is an excellent experience in a situation where the company is planning an IPO.", says Torbjørn Bjerke, CEO of Karolinska Development.
Benjamin will be responsible for Communication and Investor Relations but will also retain his former responsibility for Business Analysis. As a part of this change, Benjamin will be part of Karolinska Development’s management team.
Benjamin is M.Sc. in molecular biology and he has a degree from Uppsala Graduate School in Biomedical Research. Prior to Karolinska Development, he was head of the healthcare analyst team at Kaupthing Bank.
For further information, please contact:
Torbjørn Bjerke, CEO
Karolinska Development AB
Phone: +46 (0)72 744 41 23
torbjorn.bjerke@karolinskadevelopment.com
TO THE EDITORS
About Karolinska Development Karolinska Development aims to create value for investors, patients, and researchers by developing innovations from world class research into products that can be sold or out‐licensed with high returns. The business model is to: SELECT the most commercially attractive medical innovations; DEVELOP these to the stage where the greatest return on investment can be achieved; and COMMERCIALIZE the innovations through the sale of companies or out licensing of products. This will result in upfront payments, milestone payments and royalties.
An exclusive deal flow agreement with Karolinska Innovations, along with cooperation agreements with other leading Nordic universities, ensures the first right of refusal to a continuous flow of innovations.
Karolinska Developments flexible exit strategy enables projects to be exited at whichever stage of development offers the greatest return on investment, usually after Phase II clinical trials have indicated the desired pharmaceutical effect on patients – this being an important value enhancing step.
Today, the portfolio consists of over 40 projects at various stages, from concept development to Phase II clinical trials, twelve projects are in clinical trials with six in Phase II. The portfolio is particularly strong in the areas of cancer, dermatology, inflammation, cardiovascular disease, women’s health and diseases that affect the central nervous system. www.karolinskadevelopment.com
